January 8, 2009 - 3/A: Initial statement of beneficial ownership of securities

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Reich Michael

2. Date of Event Requiring Statement (Month/Day/Year)
03/27/2007

3. Issuer Name and Ticker or Trading Symbol
Opko Health, Inc. [OPK]

(Last)

(First)

(Middle)

OPKO HEALTH, INC., 4400 BISCAYNE BOULEVARD

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)
03/29/2007

(Street)

MIAMI, FL 33137

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $0.01 par value	359,566	D
Common Stock, $0.01 par value	194,604	I	See footnote ⁽¹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Warrant (Right to Buy)	⁽²⁾	03/27/2017	Common Stock	10,901	$ 0.6728	D
Warrant (Right to Buy)	⁽²⁾	03/27/2017	Common Stock	10,901	$ 0.8473	D
Warrant (Right to Buy)	⁽²⁾	03/27/2017	Common Stock	10,901	$ 1.0466	D
Stock Option (Right to Buy)	⁽³⁾	12/11/2013	Common Stock	62,273	$ 0.04	D
Stock Option (Right to Buy)	⁽³⁾	11/08/2014	Common Stock	25,947	$ 0.04	D
Stock Option (Right to Buy)	⁽³⁾	02/15/2015	Common Stock	103,788	$ 0.04	D
Stock Option (Right to Buy)	⁽⁴⁾	02/28/2016	Common Stock	155,682	$ 0.05	D
Warrant (Right to Buy)	⁽²⁾	03/27/2017	Common Stock	5,900	$ 0.6728	I	See footnote ⁽⁵⁾
Warrant (Right to Buy)	⁽²⁾	03/27/2017	Common Stock	5,900	$ 0.8473	I	See footnote ⁽⁵⁾
Warrant (Right to Buy)	⁽²⁾	03/27/2017	Common Stock	5,900	$ 1.0466	I	See footnote ⁽⁵⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Reich Michael OPKO HEALTH, INC. 4400 BISCAYNE BOULEVARD MIAMI, FL 33137	X

Signatures

/s/ Kate Inman, Attorney-in-Fact		01/08/2009
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The 194,604 shares of Common Stock are held by Edonjes LLC, of which Mr. Reich's children are the beneficial owners. Mr. Reich disclaims beneficial interest of the shares of Common Stock held by Edonjes LLC, except to the extent of any pecuniary interest therein.
(2)	These warrants are currently exercisable.
(3)	These options are fully vested.
(4)	56,219 of these options are fully vested. The balance will vest monthly until fully vested in December 2009.
(5)	These warrants of Common Stock are held by Edonjes LLC, of which Mr. Reich's children are the beneficial owners. Mr. Reich disclaims beneficial interest of the warrants to purchase shares of Common Stock held by Edonjes LLC, except to the extent of any pecuniary interest therein.
Remarks: All securities described were acquired in a merger transaction between Acuity Pharmaceuticals, Inc. and eXegenics, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.